A new research study claimed strong results for a combination of two off-label drugs, Ivermectin and Fenbendazole in fighting cancer; but is it flawed science?
Ivermectin, IVM, is a 1976 approved insecticide for Human use. It was dubbed the safest drug they ever had to approve, by the FDA. It was used in Africa to fight West Nile Virus and had a lot of fans who used it to fight Covid. It also has a fair amount of preclinical work showing that it might fight cancer and cancer stem cells. This link takes you to more about the research on Ivermectin with cancer.
Mebendazole is a drug licensed for Human Use and known to kill worms and fluke by damaging tubulin in their microtubules, which act as a feeding and energy network. Cancer cells have a similar network. Indeed, there is a drug, not without side-effects, called Vincristine that was designed to do exactly this with cancer cells. This link takes you to more about the research on Mebendazole with cancer.
The researchers analyzed a prospective observational group of 197 cancer patients who were prescribed 25 mg of ivermectin and 250 mg of mebendazole off-label drugs through a telemedicine platform by licensed U.S. healthcare providers. The initial 197 people had all sorts of cancers with the two highest being Prostate cancer and breast cancer. When baseline data was collected; they had an average age of 67 years, with 47.7% women and on average had had their cancers for 1.2 years with 37.1% experiencing active disease progression.
A total of 122 people completed the 6 month follow up survey (69.9%). 66.4% remaining on the protocol at 6 months and 86.9% of participants completing the full initial 90-capsule ivermectin-mebendazole prescription.
32.8% reported No Evidence of Disease
15.6% reported Regression
36.1% reported Stable Disease
15.6% reported Disease Progression
Side effects were only reported by a quarter of people and were minor.
However, about two thirds of participants reported having conventional treatment alongside the off-labels - chemotherapy (27.9%), radiation therapy (21.3%), and surgery (19.7%) - and a high proportion took supplements (49.2%), or changed their diet (37.7%). Other integrative approaches were also incorporated.
Chris Woollams comments, “As an Oxford University trained scientist, the flaws in this research are clear. For example if at the reporting point we looked at those who had only had Chemotherapy, Radiotherapy and/or surgery, how many would have been NED, or would have cancer regression or stable disease. A prospective study is supposed to establish causal benefits. This doesn’t.
I’m sure I could put supplements and green juices with the Oncologists drugs or radiotherapy and achieve much the same results or better.
I know people are jumping up and down lauding the results but, frankly, I’m not impressed. I think it is indicative that there could be benefit in these two off-label drugs, but it is by no means ‘proven’ by this research.”
Go to: Is a Combination of Fenbendazole and Ivermectin a real cancer killer.
***********
References
1. Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort: Nicholas Hulscher et al; April 2026 DOI:10.5281/zenodo.19455636